CTLA-4—two pathways to anti-tumour immunity?

Frank J Ward; Paul T Kennedy; Farah Al-Fatyan; Lekh N Dahal; Rasha Abu-Eid

doi:10.1093/immadv/ltaf008

. 2025 Mar 7;5(1):ltaf008. doi: 10.1093/immadv/ltaf008

CTLA-4—two pathways to anti-tumour immunity?

Frank J Ward ^1,^✉, Paul T Kennedy ², Farah Al-Fatyan ^3,^b, Lekh N Dahal ⁴, Rasha Abu-Eid ^5,⁶

PMCID: PMC12012449 PMID: 40265076

Abstract

Immune checkpoint inhibitor (ICI) therapies have revolutionized cancer therapy and improved patient outcomes in a range of cancers. ICIs enhance anti-tumour immunity by targeting the inhibitory checkpoint receptors CTLA-4, PD-1, PD-L1, and LAG-3. Despite their success, efficacy, and tolerance vary between patients, raising new challenges to improve these therapies. These could be addressed by the identification of robust biomarkers to predict patient outcome and a more complete understanding of how ICIs affect and are affected by the tumour microenvironment (TME). Despite being the first ICIs to be introduced, anti-CTLA-4 antibodies have underperformed compared with antibodies that target the PD-1/PDL-1 axis. This is due to the complexity regarding their precise mechanism of action, with two possible routes to efficacy identified. The first is a direct enhancement of effector T-cell responses through simple blockade of CTLA-4—‘releasing the brakes’, while the second requires prior elimination of regulatory T cells (T_REG) to allow emergence of T-cell-mediated destruction of tumour cells. We examine evidence indicating both mechanisms exist but offer different antagonistic characteristics. Further, we investigate the potential of the soluble isoform of CTLA-4, sCTLA-4, as a confounding factor for current therapies, but also as a therapeutic for delivering antigen-specific anti-tumour immunity.

Keywords: immune checkpoint inhibitor, CTLA-4, regulatory T cells (Treg), soluble CTLA-4 (sCTLA-4)

Graphical Abstract

Introduction

Checkpoint inhibitor immunotherapies (ICIs) that modulate T-cell function offer new and exciting prospects for the treatment of cancer [1, 2]. From their first introduction in 2011, this approach, in which antibodies are used to block key inhibitory receptor checkpoints CTLA-4, PD-1 on T cells, and PD-L1 on tumour cells, has led them to be used as first-line treatments for several cancers, with more clinical trials in progress. Anti-PD-1 antibodies have been at the forefront of this success but the first of the ICI to be introduced, anti-CTLA-4 antibodies, have faced difficulties preventing broad therapeutic application, despite evidence of an enduring anti-tumour immunity in some cancers, notably melanoma. This review will examine how antibodies specific for CTLA-4 enhance anti-tumour immunity and highlight a largely unrecognized novel function, masked by current anti-CTLA-4 antibodies.

The PD-1/PD-L1 antibodies—model checkpoint inhibitors

The anti-PD-1/PD-L1 antibodies are efficacious, clearly demonstrating that the strategy of simple antibody blockade of checkpoint receptor activity induces profound clinical benefits [3–12]. The premise of their activity came following initial analyses of tumour tissue biopsies showing increased tumour cell expression of the PD-1 ligands, PD-L1, and PD-L2 [13–17]. In turn, this revealed an immune escape mechanism, which could be blocked by targeting either the PD-1 receptor on T cells or PD-L1 on cancer cells. Identification of this immune evasion strategy from tumour tissue biopsy staining also revealed PD-L1 to be present in varying amounts, an observation which now supports its use as a biomarker to stratify patients likely to be responsive to anti-PD-1/PD-L1 therapies [18]. There remains, however, a need for improved patient stratification biomarkers and alternative options for patients unresponsive to PD-1/PD-L1 therapies.

Of the seven anti-PD-1 antibodies now approved for use by the FDA/EMA (Table 1), all of them use the IgG₄ subclass backbone, to avoid T-cell toxicity through Fc-dependent effector functions. Thus, a simple blockade of function is the aim, and these antibodies achieve that. For the four approved anti-PD-L1 antibodies, it is slightly more complicated; atezolizumab was developed as an IgG₁ antibody, but aglycosylated through an N297A mutation that limits antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cell-mediated phagocytosis (ADCP) [5]. Durvalumab, another IgG₁ anti-PD-L1 antibody has three Fc domain mutations that also prevent ADCC/ADCP [7]. In contrast, avelumab is an unmodified IgG₁ antibody, which has the potential to induce ADCC and ADCP [6]. In 2024, sugemalimab, the first anti-PD-L1 antibody to use the IgG₄ format, was approved for the treatment of non-small-cell lung cancer (NSCLC) [19]

Table 1.

Currently approved checkpoint inhibitor antibodies

Name	Antibody subclass	First approved(year)	ADCC/ADCP potential	Notes
CTLA-4
Ipilimumab	IgG₁	2011	✓✓✓✓✓✓
Tremelimumab	IgG₂	2022	✓✘	Approved for use in combination with durvalumab (unresectable hepatocellular carcinoma) or in combination with durvalumab and platinum-based chemotherapy (non-small-cell lung cancer)
PD-1
Nivolumab	IgG₄	2014	✓✘
Pembrolizumab	IgG₄	2014	✓✘
Cemiplimab	IgG₄	2018	✓✘
Dostarlimab	IgG₄	2021	✓✘
Retifanlimab	IgG₄	2023	✓✘
Toripalimab	IgG₄	2023	✓✘
Tislelizumab	IgG₄	2023	✓✘
PD-L1
Atezolizumab	IgG₁	2016	✓✘	Fc disabled via an N297A mutation to remove glycosylation—allows binding only to FcgRI
Durvalumab	IgG₁	2017	✘	Fc disabled via a triple mutation (L234F/L235E/P331S) to prevent all FcgR binding
Avelumab	IgG₁	2017	✓✓✓✓✓
Sugemalimab	IgG₄	2024	✓✘
LAG-3
Relatlimab	IgG₄	2022	✓✘	Approved for use in combination with nivolumab for malignant melanoma

Open in a new tab

The simple antibody blockade approach of these antibodies combined with a biomarker that supports clinical decision-making has rendered the PD-1/PD-L1 antibodies hugely successful in the treatment of many cancers. Currently, they are in more than 3000 clinical trials for a broad range of cancers, either as mono- or combination therapies. There are 5 more anti-PD-1/PD-L1 antibodies under regulatory review and at least 10 more in late-stage development [20]. Global sales of PD-1/PD-L1 checkpoint inhibitor therapies exceed $40 billion per annum despite their relatively recent first introduction in 2014. Simple antibody blockade works for the PD-1/PD-L1 axis and they therefore represent ‘model’ checkpoint inhibitors but this is not the case for anti-CTLA-4 antibodies, which although influencing the naïve T-cell response at a more fundamental level than the PD-1/PD-L1 axis have seen less clinical success.

Characteristics of CTLA-4

CTLA-4 was first described as a receptor in activated cytotoxic T cells [21]. In humans, the CTLA-4 gene (CD152) is located on chromosome 2q33 [22] next to the partially homologous gene encoding the CD28 costimulatory receptor. During naïve T-cell activation, CD28 provides the costimulatory signal by binding its ligands CD80/CD86 on antigen-presenting cells to induce full activation of the cognate, antigen-specific T-cell response mediated by T-cell receptor recognition of peptide antigen presented by Class I or II MHC molecules [23]. CTLA-4 competes with CD28 to modulate or suppress T activity after activation by binding CD80/CD86 [24]. CTLA-4 binds both CD80 and CD86 with higher affinity and avidity than CD28 allowing dominion of the inhibitory response and therefore plays an important role in maintaining immune homeostasis and tolerance to self-tissues [24, 25] The importance of CTLA-4 was demonstrated by CTLA-4 knockout mice, which die postnatally from activated immune T-cell infiltrates in tissues and organs [26, 27]. A soluble fusion protein form of CTLA-4, CTLA4-Ig, rescues these CTLA-4^KO mice [28] and chimeric mice carrying a mix of effectively CTLA-4⁺ and CTLA-4^KO T cells are also rescued [29]. In adult mice rendered CTLA-4 deficient, autoimmune pathology is present but not lethal [30]. From these experiments, we interpret that CTLA-4 plays an active role in immune homeostasis in two distinct ways. CTLA-4 expressed on effector T cells intrinsically controls the activation status of the individual cell, but CTLA-4 also plays a broader role by controlling activated cell populations in an extrinsic manner.

The role of CTLA-4 in regulatory T cells (T_REG)

Control of activated effector T-cell populations by CTLA-4 is most likely mediated by T_REG which, unlike effector T cells, express CTLA-4 constitutively and at higher cell surface levels [31, 32]. The FoxP3 transcription factor, which is the defining signature marker of regulatory T cells, controls the potency of the regulatory function [33]. Whether naturally expressed or induced, Foxp3 mediates the suppressive function of T_REGs through multiple mechanisms including the secretion of inhibitory cytokines, the depletion of IL-2 through their high expression of its receptor CD25, the selective hydrolysis of the energenic molecules ATP/ADP or active production of immunosuppressive cytokines and constitutive surface expression of CTLA-4 [34]. The role of CTLA-4 in T_REG function is of relevance to cancer immunotherapy, where inhibiting T_REGs has been shown to improve anti-tumour immune responses and prognosis both in animal models and in clinical studies. Multiple strategies have been studied for targeting T_REGs such as depleting CD4⁺CD25⁺ cells using anti-CD25 antibodies [35], selectively inhibiting T_REGs through targeting the PI3K/Akt pathway [36, 37], low-dose cyclophosphamide, and as a direct result of ICI targeting PD-1/PDL-1 and CTLA-4 (alone or in combination with other therapies) [38]. Depleting T_REGs within the TME is, therefore, of importance, and targeting CTLA-4 antibody either to block CTLA-4 function or to actively target and deplete T_REGs represent valid strategies for inducing potent anti-tumour activity.

In terms of how CTLA-4 on T_REGs functions physically to inhibit activated effector T-cell populations and the immune response, there is evidence that CD80/CD86 removal from APC cell surfaces is mediated by transendocytosis in which CTLA-4 binds to and internalizes CD80/CD86 ligands to suppress indirectly the costimulatory signal [39, 40]. Removal of CD80 also exposes and increases PD-L1 levels to further inhibit T-cell responses by binding PD-1 [41]. Other recognized mechanisms mediated by CTLA-4 include induction of the kynurenine pathway and release of indoleamine 2,3 dioxygenase to reduce the availability of the essential amino acid tryptophan [42], or simply CTLA-4-mediated blockade of CD80/CD86 ligand availability to its costimulatory homologue, CD28 [43].

Anti-CTLA-4 antibodies—the first checkpoint inhibitors

Antibodies to CTLA-4 have made a successful transition from bench to bedside for the treatment of several cancers, but there is uncertainty about how they achieve their anti-tumour effects. In fact, there was uncertainty regarding anti-CTLA-4 antibody function before the emergence of ipilimumab as the first ICI in 2011 [44]. In contrast with the notion of inducing anti-tumour activity, initial anti-CTLA-4 blockade data were ambiguous with evidence that anti-CTLA-4 mAbs enhanced mixed lymphocyte responses but also suppressed effector T cells activated by agonist anti-CD3 and CD28 mAbs [45, 46]. In another study, anti-CTLA-4 antibodies actually induced apoptosis of activated T cells [47]. Anti-CTLA-4 antibody Fab fragments, however, did not suppress T-cell activity, supporting the notion that a CTLA-4 crosslinking effect underpinned the suppressive mechanisms of anti-CTLA-4 antibody activity [46]. In effect, anti-CTLA-4 antibodies have some capacity to act as activational antagonists by enhancing the inhibitory effects of CTLA-4 function, contrasting with the costimulatory agonist effects mediated by most anti-CD28 antibodies [48].

Contrasting with these studies of anti-CTLA-4 antibody-mediated inhibitory effects on T-cell activation were clear demonstrations of anti-tumour activity in several mouse models, supporting the potential for treating patients with anti-CTLA-4 antibodies [49–53]. One notable observation was that in addition to anti-tumour activity, the application of anti-CTLA-4 antibodies established a specific protective memory response against the tumour following treatment with anti-CTLA-4 antibodies, opening the possibility of a post-tumour vaccination effect [49, 50, 53]. Critical to the productive anti-tumour immune response were T cells, and in the B16-BL6 melanoma model, CD8⁺ T cells [53]. This uncertainty of how anti-CTLA-4 antibodies on one hand appear to actively inhibit T-cell responses, but nevertheless have the capacity to augment T-cell-mediated anti-tumour responses is difficult to reconcile, and on top of that there is less information regarding effects on human T-cell-mediated immunity in vitro. One study, however, has shown that anti-CTLA-4 antibodies do also inhibit antigen-specific T-cell responses [54].

Ipilimumab, the first human anti-CTLA-4 checkpoint inhibitor

Ipilimumab, a fully human IgG₁ anti-CTLA-4 antibody, was first approved for use in 2011, initially as a novel therapy for Stage 4 malignant melanoma [44]. Ipilimumab was the first therapy to show a clear increase in both overall survival and progression-free survival in advanced melanoma patients for over 30 years [55]. It heralded a new dawn for the treatment of melanoma, and in parallel with the anti-PD-1/PD-L1 therapies, for cancers more generally. There was, however, a curious caveat. Patients receiving anti-CTLA-4 therapy sometimes exhibit a delayed response for some weeks or months before anti-tumour immunity becomes apparent [56]. In the absence of a response biomarker, this manifestation contributes to clinical uncertainty, especially as it can take the form of pseudo-disease progression as well as a simultaneous mix of disease progression and response. Why does it take so long for the adaptive immune system to mobilize anti-tumour efficacy? This is not the case for the anti-PD-1/PD-L1 antibodies where late responders are less frequently observed, at least in melanoma [57]. Despite this clinical uncertainty, analysis of malignant melanoma patients responsive to anti-CTLA-4 ipilimumab therapy who were monitored over a period of more than 10 years revealed that they appear to have gained long-term protection, supporting the possibility of a post-tumour vaccine effect [58].

Currently, the only other anti-CTLA-4 antibody approved for clinical use is tremelimumab, a human IgG₂ antibody, that received orphan drug designation for the treatment of mesothelioma in 2015, and more recently was approved as a combination therapy with durvalumab (anti-PD-L1) for adult patients with unresectable hepatocellular carcinoma [59] and further, in combination with durvalumab and platinum-based chemotherapy for a subtype of metastatic NSCLC [60]. Despite its late approval compared with ipilimumab, tremelimumab appears to be better tolerated, as a lower frequency of hypophysitis was observed in a clinical trial involving melanoma patients than typically seen with ipilimumab, likely due to reduced complement activation by the IgG₂ antibody subclass [61]

The CTLA-4 antibodies—releasing the brakes or eliminating T_REGs in murine models

How do anti-CTLA-4 antibodies achieve their function? It is not straightforward. Originally, a simple blockade of CTLA-4 was proposed, with the notion of ‘releasing the brakes’ by boosting the anti-tumour T-cell response [62]. Several groups, however, have used murine models to evaluate the mechanism of anti-CTLA-4 activity, providing evidence that the killing of immune cells is required for anti-tumour activity to occur (Figure 1) [63–72]. These target cells are posited to be intratumoural T_REG, thus, anti-CTLA-4 antibodies bind CTLA-4, expressed at higher levels on this T_REG subset, consequently eliminating them via Fc-receptor-mediated ADCC, and allowing an effector T-cell response to dominate. The antibody Fc domain is, therefore, critical to their anti-tumour function, because reformatting antibodies onto a benign subclass or Fc silent background, completely abolishes their efficacy [63–66, 68–71]. Most murine anti-CTLA-4 antibodies utilize the more aggressive IgG_2a or IgG_2b Fc backgrounds that when switched to a benign IgG₁, Fc silent, or are- removed altogether, limis any capacity for Fc-receptor-mediated ADCC. This contrasts with the approach taken with anti-PD-1 antibodies, which do not rely on an Fc domain that can mediate ADCC (Table 1). Which type of immune cells induce this intratumoural T_REG obliteration is not well-defined, but NK cells and atypical monocyte/macrophage subsets have been identified as the most likely contenders, based on intratumoural availability and relatively high expression of effector Fc receptors [65–67, 72]. A corollary to these murine studies of anti-CTLA-4 Fc effector dependency is the effects on gastrointestinal inflammation, which in concert with a loss of anti-CTLA-4 efficacy, are also reduced when an ADCC-inducing antibody Fc subclass is replaced with a benign or silent Fc background [73].

Anti-CTLA-4 antibodies kill regulatory T cells to promote anti-tumour immunity — Anti-CTLA-4 antibody-dependent T_REG apoptosis increases immune-cell-mediated tumour destruction in murine models. Antibodies specific for CTLA-4 bind the CTLA-4 receptor, which is expressed at high levels on T_REG within the tumour microenvironment and induce ADCC to render them apoptotic. This results in an increase in immune effector cell activity, leading to tumour destruction. The requirement for ADCC mediated T_REG destruction is Fc domain dependent, which is also associated with bystander autoimmunity, especially gut inflammatory responses (https://biorender.com/i67o286).

One further study, however, demonstrated clear anti-CTLA-4-mediated anti-tumour activity that did not require FcgR-mediated destruction of T_REG. Sato et al. used H11-HLE, a high-affinity-variable heavy-chain fragment, derived from a heavy-chain-only alpaca anti-CTLA-4 antibody. In both MC38 (colon adenocarcinoma) and H22 (hepatoma) mouse tumour models they revealed anti-tumour activity, which was Fc independent [74]. Further, they also indicated that the human antibody, ipilimumab, required Fc effector function for efficacy in the murine MC38 model, but observed a retained anti-tumour activity in the H22 model when its Fc effector function was ablated [74]. Similarly, a human anti-OX40 antibody, ATOR-1015, rendered bispecific by attachment of anti-CTLA-4 Fab domains, modified from CD86, to the C terminal anterior of each light chain, demonstrated both the ability to enhance antigen-specific immune responses and to deplete T_REG in human OX40 ‘knock in’ hOX40tg mice [75]. Overall, these latter studies hint at two separate mechanisms of anti-CTLA-4-mediated anti-tumour immunity, the first dependent on T_REG depletion (Figure 1), but the second more akin to the concept of ‘releasing the brakes’ in which simple blockade is capable of generating productive immunity (Figure 2).

Some anti-CTLA-4 antibodies "release the brakes" by blocking the function of CTLA-4 and enhancing anti-tumour immunity — Inhibition of CTLA-4 or sCTLA-4 induces anti-tumour immunity. Non-depleting antibodies specific for CTLA-4 or antibodies selective for the soluble sCTLA-4 isoform, can induce tumour destruction without destruction of T_REG (https://biorender.com/r45t001).

The CTLA-4 antibodies—releasing the brakes or eliminating T_REGs—human studies

In humans, it is less clear whether T_REG ablation is required for efficacy. It is, of course, difficult to study such aspects in patients, but there is some evidence for both T_REG elimination and activation via simple antibody-mediated CTLA-4 blockade. An initial study in which human nonclassical monocytes (CD14⁺CD16⁺⁺) from patients responsive to ipilimumab were examined, highlighted an increase in peripheral numbers of this monocyte subset compared with unresponsive patients, together with a demonstration of direct T_REG killing in the presence of ipilimumab, in vitro [76]. Analysis of the TME from matched biopsies of patients treated with ipilimumab, however, indicated that T_REG depletion was not necessary for efficacy [77]. Analysis of a mouse model, in which human anti-CTLA-4 antibodies were investigated using humanized Fc receptors, revealed that both ipilimumab and tremelimumab have the potential to eliminate T_REG from the TME via ADCC [67]. Further analysis with Fc-region-modified anti-CTLA-4 mAbs to enhance ADCC capacity also provided support for T_REG depletion as an important mechanism of action, but further, indicated a concurrent reduction in effector CD8⁺ T-cell numbers [78, 79] suggesting that activated effector cells expressing CTLA-4 might also be deleted.

The soluble isoform of CTLA-4

Most CTLA-4 research and clinical translation have focused on the full-length CTLA-4 receptor isoform, but other isoforms exist and contribute to immune regulation [80–83]. In mice, there are four isoforms comprising the full-length CTLA-4 encoded by exons 1, 2, 3, and 4, ligand-independent CTLA-4 (liCTLA-4; exons 1, 3, and 4), a secretable soluble isoform (sCTLA-4; exons 1, 2, and 4) and small peptide fragment encoded by exons 1 and 4 [81]. In humans, liCTLA-4 is not encoded [83]. The C terminal domain of sCTLA-4 and the peptide fragment is affected by a frameshift during translation giving rise to a different amino acid sequence compared to full-length CTLA-4. Of note, a cysteine residue at position 120, responsible for homodimerization of the CTLA-4 receptor [84], is lost in sCTLA-4, although another is gained at position 128 [81].

Initially, sCTLA-4 was considered to be produced as a monomeric isoform and was assumed to have reduced regulatory activity compared with its receptor counterpart. Recent data, however, provided good evidence that sCTLA-4 is secreted in homodimeric form [85], and further, can bind CD80 via an RGMB receptor, to enhance its inhibitory function [86]. Other studies also confirm the functional relevance of sCTLA-4 produced by activated T_REG in suppressing T-cell responses [87], but further, in altering the phenotype of any active immune milieu toward a Th2/M2 reparative environment, which is immune suppressive and cancer promoting [88].

The influence of sCTLA-4 in serum and the TME is important because current anti-CTLA-4 antibodies can bind it and therefore high levels of sCTLA-4 can effectively impinge upon optimum dosing, a factor that is largely ignored in current therapeutic regimes. High serum levels of both sCTLA-4 and sPD-L1 identified patients with NSCLC r or gastrointestinal cancer less likely to respond to anti-PD-1 therapy, emphasizing the importance of this largely overlooked alternatively spliced isoform of CTLA-4 [89, 90]. Prior to that, a melanoma study revealed a disparity in ipilimumab response success correlating with sCTLA-4 serum levels, with high serum levels above 200 pg/mL pointing to a better patient outcome [91]. In our own human studies, we identified sCTLA-4 to be raised in a melanoma patient cohort and was immunosuppressive, comparable to artificial CTLA4-Ig [87]. In a large study of lupus patients, we found that selective blockade of sCTLA-4 also enhanced cytokine secretion following activation [92]. Further, a study of sCTLA-4 as a potential biomarker demonstrated expression patterns in oral and oropharyngeal epithelial tissues with the potential to identify premalignant dysplasia preceding development of head and neck neoplasia [93]. Finally, we find that selective blockade of sCTLA-4 enhances antigen-specific immune responses but has little effect on resting cells [94].

But could sCTLA-4 play a direct role in tumour immunity either as a novel immune evasion mechanism or as a viable target for therapy? This alternatively spliced isoform is indeed produced in some cancers. Primary melanoma cell lines were identified to produce sCTLA-4 [95] and further, mesothelioma cells were also closely associated with its production [96]. It has also been reported present by transcriptome analysis and confocal microscopy in several other cancers and cancer cell lines [86, 87].

Because the C terminal sequence of sCTLA-4 differs from that of full-length CTLA-4, we generated selective anti-sCTLA-4 antibodies [94]. In previous work, we demonstrated anti-tumour activity in the murine B16-F10 metastatic melanoma model and have identified activity in other mouse models [85, 94]. The anti-tumour activity is consistent and predictable, and moreover, by their very nature, these murine anti-sCTLA-4 antibodies cannot induce ADCC because they do not target cells and have a benign murine IgG₁ Fc backbone, approximately equivalent to human IgG₄. Therefore, this is unlike the majority of anti-CTLA-4 antibodies that do require an ADCC inductive antibody subclass, and whose activity is lost upon replacement with a benign Fc background such as murine IgG₁ [63–72]. This raises the prospect of explaining anti-tumour activity, which is not dependent on T_REG depletion and is in line with the concept of ‘releasing the brakes’ (Figure 2).

How then do we explain these discrepancies in activity between anti-CTLA-4 and anti-sCTLA-4 antibodies? Perhaps the most controversial element to address is that of antigen specificity. There is very little evidence indicating that CTLA-4 blockade with anti-CTLA-4 antibodies can induce potent antigen-specific immune responses in vitro. In fact, quite the opposite, with good evidence that crosslinking CTLA-4 on activated T cells is actively suppressive [46, 54, 94]. Selective blockade of sCTLA-4 consistently enhances antigen-specific responses in terms of cell proliferation and cytokine production in vitro, which would surely be beneficial in a clinical setting, especially in boosting tumour-associated vaccines [96–99]. Regarding anti-tumour activity in murine models, both anti-CTLA-4 and selective anti-sCTLA-4 antibodies can induce efficacious immunity (see above). Both types of antibodies are functional in some models, for example, the B16-F10 metastatic melanoma model, but do not overlap precisely. We propose that while the direct killing of T_REG, mediated by anti-CTLA-4 antibodies, is the primary mechanism through which they exert their anti-tumour effects, selective blockade of sCTLA-4 contributes to ‘releasing the brakes’ of the antigen-specific immune response (Figures 1 and 2). Thus, there are two, and to some extent, mutually exclusive routes to anti-tumour immunity. Because anti-CTLA-4 antibodies bind both CTLA-4 receptor and sCTLA-4, patient responses may also vary, depending upon levels of sCTLA-4. For instance, if most anti-CTLA-4 antibodies are binding sCTLA-4, the blockade route to productive immunity would be favoured, whereas if the CTLA-4 receptor was predominantly bound that would favour the T_REG depletion route. Two recent retrospective studies of anti-PD-1 activity in advanced NSCLC and gastric cancer patients found that combinations of soluble serum factors including high levels of sCTLA-4 were predictive of a poor response to therapy [90, 91]. It seems likely, given the immunosuppressive nature of sCTLA-4, this would also apply to other checkpoint inhibitor therapies.

In summary, there is good evidence that anti-CTLA-4 mabs have two separate routes to achieving productive cancer immunotherapy, either via T_REG depletion (Figure 1) or simple blockade of sCTLA-4 or the CTLA-4 receptor (Figure 2). It is therefore crucial to understand and reconcile the conflict between these two mechanisms to further enhance our understanding of immune homeostasis and tolerance, as well as further development of safer, efficacious ICI therapies.

Acknowledgements

The Editor-in-Chief, Tim Elliott, and handling editor, Jeanette Leusen, would like to thank reviewers, Simon Milling and an anonymous reviewer, for their contribution to the publication of this article.

Contributor Information

Frank J Ward, Medical Sciences and Nutrition, Institute of Medical Sciences, School of Medicine, University of Aberdeen, Aberdeen, United Kingdom.

Paul T Kennedy, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Farah Al-Fatyan, Medical Sciences and Nutrition, Institute of Medical Sciences, School of Medicine, University of Aberdeen, Aberdeen, United Kingdom.

Lekh N Dahal, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Rasha Abu-Eid, Medical Sciences and Nutrition, Institute of Dentistry, School of Medicine, Sciences & Nutrition, University of Aberdeen, Aberdeen, United Kingdom; School of Dentistry, College of Medicine and Health, The University of Birmingham, Birmingham, United Kingdom.

Author Contributions

Frank Ward (Conceptualization, Visualization, Writing—original draft), Paul T Kennedy (Writing—original draft, Writing—review & editing), Farah Al-Fatyan (Writing—review & editing), Lekh N Dahal (Writing—review & editing), and Rasha Abu Eid (Writing—original draft, Writing—review & editing)

Conflict of interest

F.W. and L.N.D. are named inventors on a patent entitled ‘Antibodies specifically directed to a soluble form of CTLA-4’ (Patent No. US8697845 B2). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

L.N.D. and F.J.W. were supported by a project grant from Northwest Cancer Research (NWCR) UK; L.N.D. and P.T.K. were supported by BBSRC collaborative grant BB/Y514135/1 and BBSRC pioneer award.

Ethical approval

Not applicable.

Permission to reproduce

Both Figure 1 and Figure 2 were created with BioRender. Figure 1 can be found at: https://biorender.com/i67o286 and Figure 2 can be found at: https://biorender.com/r45t001

Data availability

Not applicable. This is a review article covering already published primary data.

References

1. Torphy RJ, Schulick RD, Zhu Y.. Newly emerging immune checkpoints: promises for future cancer therapy. Int J Mol Sci 2017; 18:2642. https://doi.org/ 10.3390/ijms18122642 [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Ribas A, Wolchok JD.. Cancer immunotherapy using checkpoint blockade. Science 2018; 359:1350–5. https://doi.org/ 10.1126/science.aar4060 [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Robert C, Schachter J, Long GV. et al. ; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521–32. https://doi.org/ 10.1056/NEJMoa1503093 [DOI] [PubMed] [Google Scholar]
4. Weber JS, D’Angelo SP, Minor D. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375–84. https://doi.org/ 10.1016/S1470-2045(15)70076-8 [DOI] [PubMed] [Google Scholar]
5. Rosenberg JE, Hoffman-Censits J, Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909–20. https://doi.org/ 10.1016/S0140-6736(16)00561-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
6. Kaufman HL, Russell J, Hamid O. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17:1374–85. https://doi.org/ 10.1016/S1470-2045(16)30364-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Massard C, Gordon MS, Sharma S. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016; 34:3119–25. https://doi.org/ 10.1200/JCO.2016.67.9761 [DOI] [PMC free article] [PubMed] [Google Scholar]
8. Qin S, Kudo M, Meyer T. et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol 2023; 9:1651–9. https://doi.org/ 10.1001/jamaoncol.2023.4003 [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Mai H, Chen Q, Chen D. et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA 2023; 330:1961–70. https://doi.org/ 10.1001/jama.2023.20181 [DOI] [PMC free article] [PubMed] [Google Scholar]
10. Rao S, Anandappa G, Capdevila J. et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022; 7:100529. https://doi.org/ 10.1016/j.esmoop.2022.100529 [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Oaknin A, Tinker AV, Gilbert L. et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020; 6:1766–72. https://doi.org/ 10.1001/jamaoncol.2020.4515 [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Migden MR, Rischin D, Schmults CD. et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379:341–51. https://doi.org/ 10.1056/NEJMoa1805131 [DOI] [PubMed] [Google Scholar]
13. Dong H, Zhu G, Tamada K. et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365–9. https://doi.org/ 10.1038/70932 [DOI] [PubMed] [Google Scholar]
14. Latchman Y, Wood CR, Chernova T. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261–8. https://doi.org/ 10.1038/85330 [DOI] [PubMed] [Google Scholar]
15. Strome SE, Dong H, Tamura H. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63:6501–5. [PubMed] [Google Scholar]
16. Thompson RH, Dong H, Lohse CM. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13:1757–61. https://doi.org/ 10.1158/1078-0432.CCR-06-2599 [DOI] [PubMed] [Google Scholar]
17. Thompson RH, Dong H, Kwon ED.. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007; 13:709s–15s. https://doi.org/ 10.1158/1078-0432.CCR-06-1868 [DOI] [PubMed] [Google Scholar]
18. Herbst RS, Soria J, Kowanetz M. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563–7. https://doi.org/ 10.1038/nature14011 [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Zhou C, Wang Z, Sun Y. et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 2022; 23:220–33. https://doi.org/ 10.1016/S1470-2045(21)00650-1 [DOI] [PubMed] [Google Scholar]
20. Crescioli S, Kaplon H, Chenoweth A. et al. Antibodies to watch in 2024. MAbs 2024; 16:2297450. https://doi.org/ 10.1080/19420862.2023.2297450 [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Brunet JF, Denizot F, Luciani MF. et al. A new member of the immunoglobulin superfamily—CTLA-4. Nature 1987; 328:267–70. https://doi.org/ 10.1038/328267a0 [DOI] [PubMed] [Google Scholar]
22. Dariavach P, Mattei MG, Golstein P. et al. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18:1901–5. https://doi.org/ 10.1002/eji.1830181206 [DOI] [PubMed] [Google Scholar]
23. Greenwald RJ, Freeman GJ, Sharpe AH.. The B7 family revisited. Annu Rev Immunol 2005; 23:515–48. https://doi.org/ 10.1146/annurev.immunol.23.021704.115611 [DOI] [PubMed] [Google Scholar]
24. Collins AV, Brodie DW, Gilbert RJ. et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17:201–10. https://doi.org/ 10.1016/s1074-7613(02)00362-x [DOI] [PubMed] [Google Scholar]
25. Chambers CA, Allison JP.. Co-stimulation in T cell responses. Curr Opin Immunol 1997; 9:396–404. https://doi.org/ 10.1016/s0952-7915(97)80087-8 [DOI] [PubMed] [Google Scholar]
26. Tivol EA, Borriello F, Schweitzer AN. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541–7. https://doi.org/ 10.1016/1074-7613(95)90125-6 [DOI] [PubMed] [Google Scholar]
27. Waterhouse P, Penninger JM, Timms E. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270:985–8. https://doi.org/ 10.1126/science.270.5238.985 [DOI] [PubMed] [Google Scholar]
28. Tivol EA, Boyd SD, McKeon S. et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997; 158:5091–4. [PubMed] [Google Scholar]
29. Tivol EA, Gorski J.. Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4. J Immunol 2002; 169:1852–8. https://doi.org/ 10.4049/jimmunol.169.4.1852 [DOI] [PubMed] [Google Scholar]
30. Klocke K, Sakaguchi S, Holmdahl R. et al. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A 2016; 113:2383. [DOI] [PMC free article] [PubMed] [Google Scholar]
31. Verhagen J, Genolet R, Britton GJ. et al. CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc Natl Acad Sci U S A 2013; 110:221. [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Takahashi S, Kataoka H, Hara S. et al. In vivo overexpression of CTLA-4 suppresses lymphoproliferative diseases and thymic negative selection. Eur J Immunol 2005; 35:399–407. https://doi.org/ 10.1002/eji.200324746 [DOI] [PubMed] [Google Scholar]
33. Sakaguchi S, Mikami N, Wing JB. et al. Regulatory T cells and human disease. Annu Rev Immunol 2020; 38:541–66. https://doi.org/ 10.1146/annurev-immunol-042718-041717 [DOI] [PubMed] [Google Scholar]
34. Vignali DAA, Collison LW, Workman CJ.. How regulatory T cells work. Nat Rev Immunol 2008; 8:523–32. https://doi.org/ 10.1038/nri2343 [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Zhou S, Chen L, Qin J. et al. Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity. PLoS One 2013; 8:e73952. https://doi.org/ 10.1371/journal.pone.0073952 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
36. Ahmad S, Abu-Eid R, Shrimali R. et al. Differential PI3Kdelta signaling in CD4(+) T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Cancer Res 2017; 77:1892–904. https://doi.org/ 10.1158/0008-5472.CAN-16-1839 [DOI] [PubMed] [Google Scholar]
37. Abu-Eid R, Samara RN, Ozbun L. et al. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res 2014; 2:1080–9. https://doi.org/ 10.1158/2326-6066.CIR-14-0095 [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Abu ER, Razavi GSE, Mkrtichyan M. et al. Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res 2016; 4:377–82. [DOI] [PubMed] [Google Scholar]
39. Kennedy A, Waters E, Rowshanravan B. et al. Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation. Nat Immunol 2022; 23:1365–78. https://doi.org/ 10.1038/s41590-022-01289-w [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Qureshi OS, Zheng Y, Nakamura K. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332:600–3. https://doi.org/ 10.1126/science.1202947 [DOI] [PMC free article] [PubMed] [Google Scholar]
41. Tekguc M, Wing JB, Osaki M. et al. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci U S A 2021; 118:e2023739118. https://doi.org/ 10.1073/pnas.2023739118 [DOI] [PMC free article] [PubMed] [Google Scholar]
42. Fallarino F, Grohmann U, Vacca C. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9:1069–77. https://doi.org/ 10.1038/sj.cdd.4401073 [DOI] [PubMed] [Google Scholar]
43. Genovese MC, Becker J, Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114–23. https://doi.org/ 10.1056/NEJMoa050524 [DOI] [PubMed] [Google Scholar]
44. Hodi FS, O’Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–23. https://doi.org/ 10.1056/NEJMoa1003466 [DOI] [PMC free article] [PubMed] [Google Scholar]
45. Walunas TL, Lenschow DJ, Bakker CY. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405–13. https://doi.org/ 10.1016/1074-7613(94)90071-x [DOI] [PubMed] [Google Scholar]
46. Krummel MF, Allison JP.. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459–65. https://doi.org/ 10.1084/jem.182.2.459 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Gribben JG, Freeman GJ, Boussiotis VA. et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A 1995; 92:811–5. https://doi.org/ 10.1073/pnas.92.3.811 [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Jenkins MK, Taylor PS, Norton SD. et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991; 147:2461–6. [PubMed] [Google Scholar]
49. Leach DR, Krummel MF, Allison JP.. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734–6. https://doi.org/ 10.1126/science.271.5256.1734 [DOI] [PubMed] [Google Scholar]
50. Yang YF, Zou JP, Mu J. et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997; 57:4036–41. [PubMed] [Google Scholar]
51. Hurwitz AA, Yu TF, Leach DR. et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998; 95:10067–71. https://doi.org/ 10.1073/pnas.95.17.10067 [DOI] [PMC free article] [PubMed] [Google Scholar]
52. Kwon ED, Hurwitz AA, Foster BA. et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997; 94:8099–103. https://doi.org/ 10.1073/pnas.94.15.8099 [DOI] [PMC free article] [PubMed] [Google Scholar]
53. van Elsas A, Hurwitz AA, Allison JP.. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355–66. https://doi.org/ 10.1084/jem.190.3.355 [DOI] [PMC free article] [PubMed] [Google Scholar]
54. Rosskopf S, Leitner J, Zlabinger GJ. et al. CTLA-4 antibody ipilimumab negatively affects CD4(+) T-cell responses in vitro. Cancer Immunol Immunother 2019; 68:1359–68. https://doi.org/ 10.1007/s00262-019-02369-x [DOI] [PMC free article] [PubMed] [Google Scholar]
55. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432–3. https://doi.org/ 10.1126/science.342.6165.1432 [DOI] [PubMed] [Google Scholar]
56. Wolchok JD, Hoos A, O’Day S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412–20. https://doi.org/ 10.1158/1078-0432.CCR-09-1624 [DOI] [PubMed] [Google Scholar]
57. Khoja L, Kibiro M, Metser U. et al. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer 2016; 115:1186–92. https://doi.org/ 10.1038/bjc.2016.308 [DOI] [PMC free article] [PubMed] [Google Scholar]
58. Schadendorf D, Hodi FS, Robert C. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889–94. https://doi.org/ 10.1200/JCO.2014.56.2736 [DOI] [PMC free article] [PubMed] [Google Scholar]
59. Abou-Alfa GK, Lau G, Kudo M. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1:EVIDoa2100070. https://doi.org/ 10.1056/EVIDoa2100070 [DOI] [PubMed] [Google Scholar]
60. Johnson ML, Cho BC, Luft A. et al. ; POSEIDON investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol 2023; 41:1213–27. https://doi.org/ 10.1200/JCO.22.00975 [DOI] [PMC free article] [PubMed] [Google Scholar]
61. Ribas A, Kefford R, Marshall MA. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616–22. https://doi.org/ 10.1200/JCO.2012.44.6112 [DOI] [PMC free article] [PubMed] [Google Scholar]
62. Pardoll D. Releasing the brakes on antitumor immune response. Science 1996; 271:1691. https://doi.org/ 10.1126/science.271.5256.1691 [DOI] [PubMed] [Google Scholar]
63. Bulliard Y, Jolicoeur R, Zhang J. et al. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92:475–80. https://doi.org/ 10.1038/icb.2014.26 [DOI] [PubMed] [Google Scholar]
64. Bulliard Y, Jolicoeur R, Windman M. et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210:1685–93. https://doi.org/ 10.1084/jem.20130573 [DOI] [PMC free article] [PubMed] [Google Scholar]
65. Selby MJ, Engelhardt JJ, Quigley M. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1:32–42. https://doi.org/ 10.1158/2326-6066.CIR-13-0013 [DOI] [PubMed] [Google Scholar]
66. Simpson TR, Li F, Montalvo-Ortiz W. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma,. J Exp Med 2013; 210:1695–710. https://doi.org/ 10.1084/jem.20130579 [DOI] [PMC free article] [PubMed] [Google Scholar]
67. Arce Vargas F, Furness AJS, Litchfield K. et al. ; TRACERx Melanoma. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 2018; 33:649–63.e4. https://doi.org/ 10.1016/j.ccell.2018.02.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
68. Sanseviero E, O’Brien EM, Karras JR. et al. Anti-CTLA-4 activates intratumoral NK cells and combined with IL15/IL15Ralpha complexes enhances tumor control. Cancer Immunol Res 2019; 7:1371–80. https://doi.org/ 10.1158/2326-6066.CIR-18-0386 [DOI] [PMC free article] [PubMed] [Google Scholar]
69. Du X, Tang F, Liu M. et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 2018; 28:416–32. https://doi.org/ 10.1038/s41422-018-0011-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
70. Ingram JR, Blomberg OS, Rashidian M. et al. Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A 2018; 115:3912–7. https://doi.org/ 10.1073/pnas.1801524115 [DOI] [PMC free article] [PubMed] [Google Scholar]
71. Lax BM, Palmeri JR, Lutz EA. et al. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Proc Natl Acad Sci U S A 2023; 120:e2300895120. https://doi.org/ 10.1073/pnas.2300895120 [DOI] [PMC free article] [PubMed] [Google Scholar]
72. Yofe I, Landsberger T, Yalin A. et al. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcgammaR engagement and type I interferon signaling. Nat Cancer 2022; 3(11):1336–50. https://doi.org/ 10.1038/s43018-022-00447-1 [DOI] [PubMed] [Google Scholar]
73. Bauche D, Mauze S, Kochel C. et al. Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcgammaR interactions. J ImmunoTher Cancer 2020; 8:e001584. https://doi.org/ 10.1136/jitc-2020-001584 [DOI] [PMC free article] [PubMed] [Google Scholar]
74. Sato Y, Casson CN, Matsuda A. et al. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy. Cancer Immunol Immunother 2022; 71:2421–31. https://doi.org/ 10.1007/s00262-022-03170-z [DOI] [PMC free article] [PubMed] [Google Scholar]
75. Kvarnhammar AM, Veitonmaki N, Hagerbrand K. et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J ImmunoTher Cancer 2019; 7:103–8. https://doi.org/ 10.1186/s40425-019-0570-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
76. Romano E, Kusio-Kobialka M, Foukas PG. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 2015; 112:6140–5. https://doi.org/ 10.1073/pnas.1417320112 [DOI] [PMC free article] [PubMed] [Google Scholar]
77. Sharma A, Subudhi SK, Blando J. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers. Clin Cancer Res 2019; 25:1233–8. https://doi.org/ 10.1158/1078-0432.CCR-18-0762 [DOI] [PMC free article] [PubMed] [Google Scholar]
78. Ha D, Tanaka A, Kibayashi T. et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci U S A 2019; 116:609–18. https://doi.org/ 10.1073/pnas.1812186116 [DOI] [PMC free article] [PubMed] [Google Scholar]
79. Tanaka A, Sakaguchi S.. Targeting Treg cells in cancer immunotherapy. Eur J Immunol 2019; 49:1140–6. https://doi.org/ 10.1002/eji.201847659 [DOI] [PubMed] [Google Scholar]
80. Oaks MK, Hallett KM.. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164:5015–8. https://doi.org/ 10.4049/jimmunol.164.10.5015 [DOI] [PubMed] [Google Scholar]
81. Oaks MK, Hallett KM, Penwell RT. et al. A native soluble form of CTLA-4. Cell Immunol 2000; 201:144–53. https://doi.org/ 10.1006/cimm.2000.1649 [DOI] [PubMed] [Google Scholar]
82. Magistrelli G, Jeannin P, Herbault N. et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29:3596–602. https://doi.org/ 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y [DOI] [PubMed] [Google Scholar]
83. Ueda H, Howson JM, Esposito L. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506–11. https://doi.org/ 10.1038/nature01621 [DOI] [PubMed] [Google Scholar]
84. Linsley PS, Nadler SG, Bajorath J. et al. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules. J Biol Chem 1995; 270:15417–24. https://doi.org/ 10.1074/jbc.270.25.15417 [DOI] [PubMed] [Google Scholar]
85. Kennedy PT, Saulters EL, Duckworth AD. et al. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. Mol Ther 2024; 32:457–68. https://doi.org/ 10.1016/j.ymthe.2023.11.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
86. Sekiya T, Takaki S.. RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4. Sci Rep 2019; 9:6984–y. https://doi.org/ 10.1038/s41598-019-43068-y [DOI] [PMC free article] [PubMed] [Google Scholar]
87. Khanolkar RC, Zhang C, Al-Fatyan F. et al. TGFbeta2 induces the soluble isoform of CTLA-4—implications for CTLA-4 based checkpoint inhibitor antibodies in malignant melanoma. Front Immunol 2022; 12:763877. [DOI] [PMC free article] [PubMed] [Google Scholar]
88. Osaki M, Sakaguchi S.. Soluble CTLA-4 mainly produced by Treg cells inhibits type 1 inflammation without hindering type 2 immunity to allow for inflammation resolution. BioRxiv 2023:05.26.542386. https://doi.org/ 10.1101/2023.05.26.542386 [DOI] [Google Scholar]
89. Hayashi H, Chamoto K, Hatae R. et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J Clin Invest 2024; 134:e168318. https://doi.org/ 10.1172/JCI168318 [DOI] [PMC free article] [PubMed] [Google Scholar]
90. Oshima K, Shoji H, Boku N. et al. CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer. Am J Cancer Res 2024; 14:1174–89. https://doi.org/ 10.62347/NQBL9998 [DOI] [PMC free article] [PubMed] [Google Scholar]
91. Leung AM, Lee AF, Ozao-Choy J. et al. Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels. Front Oncol 2014; 4:110. https://doi.org/ 10.3389/fonc.2014.00110 [DOI] [PMC free article] [PubMed] [Google Scholar]
92. Dahal LN, Basu N, Youssef H. et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther 2016; 18:180–1. https://doi.org/ 10.1186/s13075-016-1075-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
93. Clare P, Al-Fatyan F, Risheh B. et al. A novel role for the soluble isoform of CTLA-4 in normal, dysplastic and neoplastic oral and oropharyngeal epithelia. Cancers (Basel) 2023; 15:1696. https://doi.org/ 10.3390/cancers15061696 [DOI] [PMC free article] [PubMed] [Google Scholar]
94. Ward FJ, Dahal LN, Wijesekera SK. et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol 2013; 43:1274–85. https://doi.org/ 10.1002/eji.201242529 [DOI] [PubMed] [Google Scholar]
95. Laurent S, Queirolo P, Boero S. et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J Transl Med 2013; 11:108. https://doi.org/ 10.1186/1479-5876-11-108 [DOI] [PMC free article] [PubMed] [Google Scholar]
96. Roncella S, Laurent S, Fontana V. et al. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor. Cancer Immunol Immunother 2016; 65:909–17. https://doi.org/ 10.1007/s00262-016-1844-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
97. Pitts SC, Schlom J, Donahue RN.. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. J Exp Clin Cancer Res 2024; 43:155–z. https://doi.org/ 10.1186/s13046-024-03074-z [DOI] [PMC free article] [PubMed] [Google Scholar]
98. Dahal LN, Schwarz H, Ward FJ.. Hiding in plain sight: soluble immunomodulatory receptors. Trends Immunol 2018; 39:771–4. https://doi.org/ 10.1016/j.it.2018.08.004 [DOI] [PubMed] [Google Scholar]
99. Abdulkhaleq F, Larossi N, Ogbonda O. et al. CTLA-4 expression by human tumor cells and its impact on immunotherapeutic strategies: a systematic review. Immuno-Oncol Insights 2021; 2(3):151–69. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable. This is a review article covering already published primary data.

[CIT0001] 1. Torphy RJ, Schulick RD, Zhu Y.. Newly emerging immune checkpoints: promises for future cancer therapy. Int J Mol Sci 2017; 18:2642. https://doi.org/ 10.3390/ijms18122642 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0002] 2. Ribas A, Wolchok JD.. Cancer immunotherapy using checkpoint blockade. Science 2018; 359:1350–5. https://doi.org/ 10.1126/science.aar4060 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0003] 3. Robert C, Schachter J, Long GV. et al. ; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521–32. https://doi.org/ 10.1056/NEJMoa1503093 [DOI] [PubMed] [Google Scholar]

[CIT0004] 4. Weber JS, D’Angelo SP, Minor D. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375–84. https://doi.org/ 10.1016/S1470-2045(15)70076-8 [DOI] [PubMed] [Google Scholar]

[CIT0005] 5. Rosenberg JE, Hoffman-Censits J, Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909–20. https://doi.org/ 10.1016/S0140-6736(16)00561-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0006] 6. Kaufman HL, Russell J, Hamid O. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17:1374–85. https://doi.org/ 10.1016/S1470-2045(16)30364-3 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0007] 7. Massard C, Gordon MS, Sharma S. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016; 34:3119–25. https://doi.org/ 10.1200/JCO.2016.67.9761 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0008] 8. Qin S, Kudo M, Meyer T. et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol 2023; 9:1651–9. https://doi.org/ 10.1001/jamaoncol.2023.4003 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0009] 9. Mai H, Chen Q, Chen D. et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA 2023; 330:1961–70. https://doi.org/ 10.1001/jama.2023.20181 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0010] 10. Rao S, Anandappa G, Capdevila J. et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022; 7:100529. https://doi.org/ 10.1016/j.esmoop.2022.100529 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0011] 11. Oaknin A, Tinker AV, Gilbert L. et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020; 6:1766–72. https://doi.org/ 10.1001/jamaoncol.2020.4515 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0012] 12. Migden MR, Rischin D, Schmults CD. et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379:341–51. https://doi.org/ 10.1056/NEJMoa1805131 [DOI] [PubMed] [Google Scholar]

[CIT0013] 13. Dong H, Zhu G, Tamada K. et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365–9. https://doi.org/ 10.1038/70932 [DOI] [PubMed] [Google Scholar]

[CIT0014] 14. Latchman Y, Wood CR, Chernova T. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261–8. https://doi.org/ 10.1038/85330 [DOI] [PubMed] [Google Scholar]

[CIT0015] 15. Strome SE, Dong H, Tamura H. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63:6501–5. [PubMed] [Google Scholar]

[CIT0016] 16. Thompson RH, Dong H, Lohse CM. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13:1757–61. https://doi.org/ 10.1158/1078-0432.CCR-06-2599 [DOI] [PubMed] [Google Scholar]

[CIT0017] 17. Thompson RH, Dong H, Kwon ED.. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007; 13:709s–15s. https://doi.org/ 10.1158/1078-0432.CCR-06-1868 [DOI] [PubMed] [Google Scholar]

[CIT0018] 18. Herbst RS, Soria J, Kowanetz M. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563–7. https://doi.org/ 10.1038/nature14011 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0019] 19. Zhou C, Wang Z, Sun Y. et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 2022; 23:220–33. https://doi.org/ 10.1016/S1470-2045(21)00650-1 [DOI] [PubMed] [Google Scholar]

[CIT0020] 20. Crescioli S, Kaplon H, Chenoweth A. et al. Antibodies to watch in 2024. MAbs 2024; 16:2297450. https://doi.org/ 10.1080/19420862.2023.2297450 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0021] 21. Brunet JF, Denizot F, Luciani MF. et al. A new member of the immunoglobulin superfamily—CTLA-4. Nature 1987; 328:267–70. https://doi.org/ 10.1038/328267a0 [DOI] [PubMed] [Google Scholar]

[CIT0022] 22. Dariavach P, Mattei MG, Golstein P. et al. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18:1901–5. https://doi.org/ 10.1002/eji.1830181206 [DOI] [PubMed] [Google Scholar]

[CIT0023] 23. Greenwald RJ, Freeman GJ, Sharpe AH.. The B7 family revisited. Annu Rev Immunol 2005; 23:515–48. https://doi.org/ 10.1146/annurev.immunol.23.021704.115611 [DOI] [PubMed] [Google Scholar]

[CIT0024] 24. Collins AV, Brodie DW, Gilbert RJ. et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17:201–10. https://doi.org/ 10.1016/s1074-7613(02)00362-x [DOI] [PubMed] [Google Scholar]

[CIT0025] 25. Chambers CA, Allison JP.. Co-stimulation in T cell responses. Curr Opin Immunol 1997; 9:396–404. https://doi.org/ 10.1016/s0952-7915(97)80087-8 [DOI] [PubMed] [Google Scholar]

[CIT0026] 26. Tivol EA, Borriello F, Schweitzer AN. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541–7. https://doi.org/ 10.1016/1074-7613(95)90125-6 [DOI] [PubMed] [Google Scholar]

[CIT0027] 27. Waterhouse P, Penninger JM, Timms E. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270:985–8. https://doi.org/ 10.1126/science.270.5238.985 [DOI] [PubMed] [Google Scholar]

[CIT0028] 28. Tivol EA, Boyd SD, McKeon S. et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997; 158:5091–4. [PubMed] [Google Scholar]

[CIT0029] 29. Tivol EA, Gorski J.. Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4. J Immunol 2002; 169:1852–8. https://doi.org/ 10.4049/jimmunol.169.4.1852 [DOI] [PubMed] [Google Scholar]

[CIT0030] 30. Klocke K, Sakaguchi S, Holmdahl R. et al. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A 2016; 113:2383. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0031] 31. Verhagen J, Genolet R, Britton GJ. et al. CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc Natl Acad Sci U S A 2013; 110:221. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0032] 32. Takahashi S, Kataoka H, Hara S. et al. In vivo overexpression of CTLA-4 suppresses lymphoproliferative diseases and thymic negative selection. Eur J Immunol 2005; 35:399–407. https://doi.org/ 10.1002/eji.200324746 [DOI] [PubMed] [Google Scholar]

[CIT0033] 33. Sakaguchi S, Mikami N, Wing JB. et al. Regulatory T cells and human disease. Annu Rev Immunol 2020; 38:541–66. https://doi.org/ 10.1146/annurev-immunol-042718-041717 [DOI] [PubMed] [Google Scholar]

[CIT0034] 34. Vignali DAA, Collison LW, Workman CJ.. How regulatory T cells work. Nat Rev Immunol 2008; 8:523–32. https://doi.org/ 10.1038/nri2343 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0035] 35. Zhou S, Chen L, Qin J. et al. Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity. PLoS One 2013; 8:e73952. https://doi.org/ 10.1371/journal.pone.0073952 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

[CIT0036] 36. Ahmad S, Abu-Eid R, Shrimali R. et al. Differential PI3Kdelta signaling in CD4(+) T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Cancer Res 2017; 77:1892–904. https://doi.org/ 10.1158/0008-5472.CAN-16-1839 [DOI] [PubMed] [Google Scholar]

[CIT0037] 37. Abu-Eid R, Samara RN, Ozbun L. et al. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res 2014; 2:1080–9. https://doi.org/ 10.1158/2326-6066.CIR-14-0095 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0038] 38. Abu ER, Razavi GSE, Mkrtichyan M. et al. Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res 2016; 4:377–82. [DOI] [PubMed] [Google Scholar]

[CIT0039] 39. Kennedy A, Waters E, Rowshanravan B. et al. Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation. Nat Immunol 2022; 23:1365–78. https://doi.org/ 10.1038/s41590-022-01289-w [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0040] 40. Qureshi OS, Zheng Y, Nakamura K. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332:600–3. https://doi.org/ 10.1126/science.1202947 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0041] 41. Tekguc M, Wing JB, Osaki M. et al. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci U S A 2021; 118:e2023739118. https://doi.org/ 10.1073/pnas.2023739118 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0042] 42. Fallarino F, Grohmann U, Vacca C. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9:1069–77. https://doi.org/ 10.1038/sj.cdd.4401073 [DOI] [PubMed] [Google Scholar]

[CIT0043] 43. Genovese MC, Becker J, Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114–23. https://doi.org/ 10.1056/NEJMoa050524 [DOI] [PubMed] [Google Scholar]

[CIT0044] 44. Hodi FS, O’Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–23. https://doi.org/ 10.1056/NEJMoa1003466 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0045] 45. Walunas TL, Lenschow DJ, Bakker CY. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405–13. https://doi.org/ 10.1016/1074-7613(94)90071-x [DOI] [PubMed] [Google Scholar]

[CIT0046] 46. Krummel MF, Allison JP.. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459–65. https://doi.org/ 10.1084/jem.182.2.459 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0047] 47. Gribben JG, Freeman GJ, Boussiotis VA. et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A 1995; 92:811–5. https://doi.org/ 10.1073/pnas.92.3.811 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0048] 48. Jenkins MK, Taylor PS, Norton SD. et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991; 147:2461–6. [PubMed] [Google Scholar]

[CIT0049] 49. Leach DR, Krummel MF, Allison JP.. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734–6. https://doi.org/ 10.1126/science.271.5256.1734 [DOI] [PubMed] [Google Scholar]

[CIT0050] 50. Yang YF, Zou JP, Mu J. et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997; 57:4036–41. [PubMed] [Google Scholar]

[CIT0051] 51. Hurwitz AA, Yu TF, Leach DR. et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998; 95:10067–71. https://doi.org/ 10.1073/pnas.95.17.10067 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0052] 52. Kwon ED, Hurwitz AA, Foster BA. et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997; 94:8099–103. https://doi.org/ 10.1073/pnas.94.15.8099 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0053] 53. van Elsas A, Hurwitz AA, Allison JP.. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355–66. https://doi.org/ 10.1084/jem.190.3.355 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0054] 54. Rosskopf S, Leitner J, Zlabinger GJ. et al. CTLA-4 antibody ipilimumab negatively affects CD4(+) T-cell responses in vitro. Cancer Immunol Immunother 2019; 68:1359–68. https://doi.org/ 10.1007/s00262-019-02369-x [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0055] 55. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432–3. https://doi.org/ 10.1126/science.342.6165.1432 [DOI] [PubMed] [Google Scholar]

[CIT0056] 56. Wolchok JD, Hoos A, O’Day S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412–20. https://doi.org/ 10.1158/1078-0432.CCR-09-1624 [DOI] [PubMed] [Google Scholar]

[CIT0057] 57. Khoja L, Kibiro M, Metser U. et al. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer 2016; 115:1186–92. https://doi.org/ 10.1038/bjc.2016.308 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0058] 58. Schadendorf D, Hodi FS, Robert C. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889–94. https://doi.org/ 10.1200/JCO.2014.56.2736 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0059] 59. Abou-Alfa GK, Lau G, Kudo M. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1:EVIDoa2100070. https://doi.org/ 10.1056/EVIDoa2100070 [DOI] [PubMed] [Google Scholar]

[CIT0060] 60. Johnson ML, Cho BC, Luft A. et al. ; POSEIDON investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol 2023; 41:1213–27. https://doi.org/ 10.1200/JCO.22.00975 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0061] 61. Ribas A, Kefford R, Marshall MA. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616–22. https://doi.org/ 10.1200/JCO.2012.44.6112 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0062] 62. Pardoll D. Releasing the brakes on antitumor immune response. Science 1996; 271:1691. https://doi.org/ 10.1126/science.271.5256.1691 [DOI] [PubMed] [Google Scholar]

[CIT0063] 63. Bulliard Y, Jolicoeur R, Zhang J. et al. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92:475–80. https://doi.org/ 10.1038/icb.2014.26 [DOI] [PubMed] [Google Scholar]

[CIT0064] 64. Bulliard Y, Jolicoeur R, Windman M. et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210:1685–93. https://doi.org/ 10.1084/jem.20130573 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0065] 65. Selby MJ, Engelhardt JJ, Quigley M. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1:32–42. https://doi.org/ 10.1158/2326-6066.CIR-13-0013 [DOI] [PubMed] [Google Scholar]

[CIT0066] 66. Simpson TR, Li F, Montalvo-Ortiz W. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma,. J Exp Med 2013; 210:1695–710. https://doi.org/ 10.1084/jem.20130579 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0067] 67. Arce Vargas F, Furness AJS, Litchfield K. et al. ; TRACERx Melanoma. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 2018; 33:649–63.e4. https://doi.org/ 10.1016/j.ccell.2018.02.010 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0068] 68. Sanseviero E, O’Brien EM, Karras JR. et al. Anti-CTLA-4 activates intratumoral NK cells and combined with IL15/IL15Ralpha complexes enhances tumor control. Cancer Immunol Res 2019; 7:1371–80. https://doi.org/ 10.1158/2326-6066.CIR-18-0386 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0069] 69. Du X, Tang F, Liu M. et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 2018; 28:416–32. https://doi.org/ 10.1038/s41422-018-0011-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0070] 70. Ingram JR, Blomberg OS, Rashidian M. et al. Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A 2018; 115:3912–7. https://doi.org/ 10.1073/pnas.1801524115 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0071] 71. Lax BM, Palmeri JR, Lutz EA. et al. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Proc Natl Acad Sci U S A 2023; 120:e2300895120. https://doi.org/ 10.1073/pnas.2300895120 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0072] 72. Yofe I, Landsberger T, Yalin A. et al. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcgammaR engagement and type I interferon signaling. Nat Cancer 2022; 3(11):1336–50. https://doi.org/ 10.1038/s43018-022-00447-1 [DOI] [PubMed] [Google Scholar]

[CIT0073] 73. Bauche D, Mauze S, Kochel C. et al. Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcgammaR interactions. J ImmunoTher Cancer 2020; 8:e001584. https://doi.org/ 10.1136/jitc-2020-001584 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0074] 74. Sato Y, Casson CN, Matsuda A. et al. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy. Cancer Immunol Immunother 2022; 71:2421–31. https://doi.org/ 10.1007/s00262-022-03170-z [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0075] 75. Kvarnhammar AM, Veitonmaki N, Hagerbrand K. et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J ImmunoTher Cancer 2019; 7:103–8. https://doi.org/ 10.1186/s40425-019-0570-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0076] 76. Romano E, Kusio-Kobialka M, Foukas PG. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 2015; 112:6140–5. https://doi.org/ 10.1073/pnas.1417320112 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0077] 77. Sharma A, Subudhi SK, Blando J. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers. Clin Cancer Res 2019; 25:1233–8. https://doi.org/ 10.1158/1078-0432.CCR-18-0762 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0078] 78. Ha D, Tanaka A, Kibayashi T. et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci U S A 2019; 116:609–18. https://doi.org/ 10.1073/pnas.1812186116 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0079] 79. Tanaka A, Sakaguchi S.. Targeting Treg cells in cancer immunotherapy. Eur J Immunol 2019; 49:1140–6. https://doi.org/ 10.1002/eji.201847659 [DOI] [PubMed] [Google Scholar]

[CIT0080] 80. Oaks MK, Hallett KM.. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164:5015–8. https://doi.org/ 10.4049/jimmunol.164.10.5015 [DOI] [PubMed] [Google Scholar]

[CIT0081] 81. Oaks MK, Hallett KM, Penwell RT. et al. A native soluble form of CTLA-4. Cell Immunol 2000; 201:144–53. https://doi.org/ 10.1006/cimm.2000.1649 [DOI] [PubMed] [Google Scholar]

[CIT0082] 82. Magistrelli G, Jeannin P, Herbault N. et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29:3596–602. https://doi.org/ 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y [DOI] [PubMed] [Google Scholar]

[CIT0083] 83. Ueda H, Howson JM, Esposito L. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506–11. https://doi.org/ 10.1038/nature01621 [DOI] [PubMed] [Google Scholar]

[CIT0084] 84. Linsley PS, Nadler SG, Bajorath J. et al. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules. J Biol Chem 1995; 270:15417–24. https://doi.org/ 10.1074/jbc.270.25.15417 [DOI] [PubMed] [Google Scholar]

[CIT0085] 85. Kennedy PT, Saulters EL, Duckworth AD. et al. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. Mol Ther 2024; 32:457–68. https://doi.org/ 10.1016/j.ymthe.2023.11.028 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0086] 86. Sekiya T, Takaki S.. RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4. Sci Rep 2019; 9:6984–y. https://doi.org/ 10.1038/s41598-019-43068-y [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0087] 87. Khanolkar RC, Zhang C, Al-Fatyan F. et al. TGFbeta2 induces the soluble isoform of CTLA-4—implications for CTLA-4 based checkpoint inhibitor antibodies in malignant melanoma. Front Immunol 2022; 12:763877. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0088] 88. Osaki M, Sakaguchi S.. Soluble CTLA-4 mainly produced by Treg cells inhibits type 1 inflammation without hindering type 2 immunity to allow for inflammation resolution. BioRxiv 2023:05.26.542386. https://doi.org/ 10.1101/2023.05.26.542386 [DOI] [Google Scholar]

[CIT0089] 89. Hayashi H, Chamoto K, Hatae R. et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J Clin Invest 2024; 134:e168318. https://doi.org/ 10.1172/JCI168318 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0090] 90. Oshima K, Shoji H, Boku N. et al. CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer. Am J Cancer Res 2024; 14:1174–89. https://doi.org/ 10.62347/NQBL9998 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0091] 91. Leung AM, Lee AF, Ozao-Choy J. et al. Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels. Front Oncol 2014; 4:110. https://doi.org/ 10.3389/fonc.2014.00110 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0092] 92. Dahal LN, Basu N, Youssef H. et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther 2016; 18:180–1. https://doi.org/ 10.1186/s13075-016-1075-1 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0093] 93. Clare P, Al-Fatyan F, Risheh B. et al. A novel role for the soluble isoform of CTLA-4 in normal, dysplastic and neoplastic oral and oropharyngeal epithelia. Cancers (Basel) 2023; 15:1696. https://doi.org/ 10.3390/cancers15061696 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0094] 94. Ward FJ, Dahal LN, Wijesekera SK. et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol 2013; 43:1274–85. https://doi.org/ 10.1002/eji.201242529 [DOI] [PubMed] [Google Scholar]

[CIT0095] 95. Laurent S, Queirolo P, Boero S. et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J Transl Med 2013; 11:108. https://doi.org/ 10.1186/1479-5876-11-108 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0096] 96. Roncella S, Laurent S, Fontana V. et al. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor. Cancer Immunol Immunother 2016; 65:909–17. https://doi.org/ 10.1007/s00262-016-1844-3 [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0097] 97. Pitts SC, Schlom J, Donahue RN.. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. J Exp Clin Cancer Res 2024; 43:155–z. https://doi.org/ 10.1186/s13046-024-03074-z [DOI] [PMC free article] [PubMed] [Google Scholar]

[CIT0098] 98. Dahal LN, Schwarz H, Ward FJ.. Hiding in plain sight: soluble immunomodulatory receptors. Trends Immunol 2018; 39:771–4. https://doi.org/ 10.1016/j.it.2018.08.004 [DOI] [PubMed] [Google Scholar]

[CIT0099] 99. Abdulkhaleq F, Larossi N, Ogbonda O. et al. CTLA-4 expression by human tumor cells and its impact on immunotherapeutic strategies: a systematic review. Immuno-Oncol Insights 2021; 2(3):151–69. [Google Scholar]

PERMALINK

CTLA-4—two pathways to anti-tumour immunity?

Frank J Ward

Paul T Kennedy

Farah Al-Fatyan

Lekh N Dahal

Rasha Abu-Eid

Roles

Abstract

Graphical Abstract

Graphical Abstract.

Introduction

The PD-1/PD-L1 antibodies—model checkpoint inhibitors

Table 1.

Characteristics of CTLA-4

The role of CTLA-4 in regulatory T cells (T_REG)

Anti-CTLA-4 antibodies—the first checkpoint inhibitors

Ipilimumab, the first human anti-CTLA-4 checkpoint inhibitor

The CTLA-4 antibodies—releasing the brakes or eliminating T_REGs in murine models

Figure 1.

Figure 2.

The CTLA-4 antibodies—releasing the brakes or eliminating T_REGs—human studies

The soluble isoform of CTLA-4

Acknowledgements

Contributor Information

Author Contributions

Conflict of interest

Funding

Ethical approval

Permission to reproduce

Data availability

References

Associated Data

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

CTLA-4—two pathways to anti-tumour immunity?

Frank J Ward

Paul T Kennedy

Farah Al-Fatyan

Lekh N Dahal

Rasha Abu-Eid

Roles

Abstract

Graphical Abstract

Graphical Abstract.

Introduction

The PD-1/PD-L1 antibodies—model checkpoint inhibitors

Table 1.

Characteristics of CTLA-4

The role of CTLA-4 in regulatory T cells (TREG)

Anti-CTLA-4 antibodies—the first checkpoint inhibitors

Ipilimumab, the first human anti-CTLA-4 checkpoint inhibitor

The CTLA-4 antibodies—releasing the brakes or eliminating TREGs in murine models

Figure 1.

Figure 2.

The CTLA-4 antibodies—releasing the brakes or eliminating TREGs—human studies

The soluble isoform of CTLA-4

Acknowledgements

Contributor Information

Author Contributions

Conflict of interest

Funding

Ethical approval

Permission to reproduce

Data availability

References

Associated Data

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

The role of CTLA-4 in regulatory T cells (T_REG)

The CTLA-4 antibodies—releasing the brakes or eliminating T_REGs in murine models

The CTLA-4 antibodies—releasing the brakes or eliminating T_REGs—human studies